Investor That Backed Moderna Raises $3.6B For AI-driven Biotech Ventures
Investor That Backed Moderna Raises $3.6B For AI-driven Biotech Ventures
In a recent development, Flagship Pioneering, the venture capital firm known for backing Moderna (NASDAQ:MRNA) has successfully secured a whopping $3.6 billion in funding.
在最近的一項發展中，以支持Moderna（納斯達克股票代碼：MRNA）而聞名的風險投資公司旗艦先鋒成功獲得了高達36億美元的融資。
What Happened: Flagship Pioneering has raised $2.6 billion for its eighth fund and an additional $1 billion for parallel funds. These parallel funds will be invested in specific sectors such as diagnostics or therapeutics. The venture firm is also planning to raise more funds for its eighth fund later this year. The funds are intended to launch a series of new biotech companies that will harness the power of generative artificial intelligence for drug discovery, The Financial Times reported on Wednesday.
發生了什麼：旗艦先鋒已經爲其第八隻基金籌集了26億美元，爲平行基金又籌集了10億美元。這些平行資金將投資於診斷或治療等特定領域。這家風險投資公司還計劃在今年晚些時候爲其第八隻基金籌集更多資金。《金融時報》週三報道，這些基金旨在創辦一系列新的生物技術公司，這些公司將利用生成人工智能的力量進行藥物發現。
Noubar Afeyan, the founder of Flagship, stated that a significant part of the investments from the eighth fund will be directed towards platforms that employ AI in innovative ways for drug development. The firm is considering ideas like using AI to create novel chemical materials for medicines and automating hypothesis generation for scientists.
Flagship的創始人努巴爾·阿菲揚表示，第八隻基金的很大一部分投資將用於以創新方式使用人工智能進行藥物開發的平台。該公司正在考慮諸如使用人工智能爲藥物創造新的化學材料以及自動爲科學家生成假設等想法。
Why It Matters: Flagship's successful fundraising signifies a positive trend for venture investment in biotech. This sector has been recovering from a downturn triggered by the end of a pandemic-induced boom and a series of interest rate hikes. Flagship's investment strategy is increasingly focusing on biotechs developing individual drugs, with at least a quarter of investments from its last fund deployed through its Pioneering Medicines arm.
爲何重要：Flagship的成功籌款標誌着生物技術風險投資的積極趨勢。該行業已經從疫情引發的繁榮結束和一系列加息引發的低迷中恢復過來。Flagship的投資策略越來越側重於開發個體藥物的生物技術公司，其上一筆基金中至少有四分之一的投資是通過其先鋒藥物部門進行的。
In April, the global AI in healthcare market size was valued at $20.9 billion and is expected to reach $148.4 billion by 2029. This indicates a growing interest in AI-driven healthcare solutions.
4月，醫療保健領域的全球人工智能市場規模爲209億美元，預計到2029年將達到1484億美元。這表明人們對人工智能驅動的醫療解決方案的興趣與日俱增。
Moreover, there is growing investment in healthtech sector. For instance, in June, SoftBank Group Corp (OTC:SFTBF) announced a joint venture with Tempus AI Inc (NASDAQ:TEM) to enhance precision medicine in Japan using AI.
此外，對醫療科技領域的投資正在增加。例如，6月，軟銀集團公司（場外交易代碼：SFTBF）宣佈與Tempus AI Inc（納斯達克股票代碼：TEM）成立合資企業，利用人工智能增強日本的精準醫療。
- Former Mike Pence Staffer Dismisses Trump's Attempts To Distance Himself From 'Project 2025' — 'Preposterous If You Look At The Collaborators'
- 前邁克·彭斯工作人員駁斥了特朗普試圖與 “2025年項目” 保持距離的企圖—— “如果你看看合作者就太荒謬了”
Image via Shutterstock
圖片來自 Shutterstock
This story was generated using Benzinga Neuro and edited by Pooja Rajkumari
這個故事是使用 Benzinga Neuro 創作的，由 Pooja Rajkumari